Oricell’s $110 Million Bet Exposes the Dirty Secret of Solid Tumor CAR-T: The Science Is Ahead of the Business Model
Oricell Therapeutics just closed a $110 million pre-IPO round to push its CAR-T platform into solid tumors. Investors are...
oncology financing